Drug Profile
Research programme: kinase inhibitors - Rottapharm Biotech
Alternative Names: CR6970Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Rottapharm Madaus
- Developer Rottapharm Biotech
- Class
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for research development in Osteoarthritis in Italy
- 15 Oct 2015 Early research in Osteoarthritis in Italy (unspecified route)